GlassScriptPhysician profile
Maria B Antonio-Miranda
NPI 1972525327
$7,597.77
in general payments reported to CMS, 2019-2025
41 companies · $1,806 in 2025
The $1,806 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $711 · 2020: $442 · 2021: $537 · 2022: $1,223 · 2023: $1,013 · 2024: $1,866 · 2025: $1,806.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,685.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,684.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,077.57 | 2019-2025 | Tezspire, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $1,198.67 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Mylan Specialty L.P. | $471.55 | 2019-2024 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $422.71 | 2021-2025 | Glassia, Cuvitru, Hyqvia |
| Actelion Pharmaceuticals US, INC. | $382.44 | 2021-2025 | Opsumit, Uptravi, Opsynvi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $348.48 | 2019-2025 | Ofev, Jascayd, Stiolto Respimat |
| Insmed, INC. | $347.86 | 2020-2025 | Arikayce, Brinsupri |
| Grifols USA, LLC | $230.64 | 2019-2025 | Prolastin-C Liquid |
| Medical Device Business Services, INC. | $214.74 | 2022 | |
| Inspire Medical Systems, INC. | $188.67 | 2023-2024 | Inspire |
| Mallinckrodt Hospital Products INC. | $169.93 | 2020-2025 | Acthar |
| Pulmonx Corporation | $146.62 | 2025 | Zephyr Endobronchial Valve, Zephyr Delivery Catheter, Chartis Catheter |
| Cook Medical LLC | $121.82 | 2024 | Amplatz |
| Inogen, INC. | $115.46 | 2022-2024 | Inogen |
| United Therapeutics Corporation | $110.97 | 2023-2025 | Tyvaso, Orenitram, Tyvaso |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $101.18 | 2019-2024 | |
| Electromed, INC. | $89.70 | 2022-2024 | Smartvest |
| Ethicon INC. | $72.40 | 2021 | |
| Merck Sharp & Dohme LLC | $72.15 | 2019-2025 | Keytruda |
| Philips North America LLC | $63.55 | 2019-2024 | (Ak6) Vest Therapy |
| Pfizer INC. | $56.72 | 2022-2023 | |
| Viatris Specialty LLC | $53.51 | 2025 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $51.57 | 2019 | |
| Vifor Pharma, INC. | $49.70 | 2025 | Zemaira |
| Shire North American Group INC | $48.21 | 2019 | |
| Ani Pharmaceuticals, INC. | $47.26 | 2022-2023 | Purified Cortrophin Gel |
| Baxter Healthcare | $31.06 | 2022 | |
| Mayne Pharma Commercial LLC | $30.41 | 2020-2021 | |
| Fisher & Paykel Healthcare INC | $29.85 | 2020-2021 | |
| 3b Medical, INC. | $29.26 | 2024 | Luna |
| Tempus Ai, INC | $28.91 | 2025 | Xt Cdx |
| Csl Behring | $28.22 | 2023 | Hizentra |
| Axsome Therapeutics, INC. | $26.64 | 2024 | Sunosi |
| Sunovion Pharmaceuticals INC. | $25.82 | 2019 | |
| Lilly USA, LLC | $21.77 | 2025 | Zepbound |
| Circassia INC. | $18.02 | 2019 | |
| Janssen Pharmaceuticals, INC | $15.96 | 2019 | |
| Jazz Pharmaceuticals INC. | $15.58 | 2021 | |
| Verona Pharma, INC. | $14.22 | 2025 | Ohtuvayre |
| Masimo Corporation | $14.05 | 2024 | Set and Rainbow Set |
| Veran Medical Technologies, INC. | $13.92 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Antonio-Miranda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.